admin – Page 4 – ERN BOND

Description of four patients with TRIP11 variants expand the clinical spectrum of odontochondroplasia (ODCD) and demonstrate the existence of common variants

Description of four patients with TRIP11 variants expand the clinical [...]

Description of four patients with TRIP11 variants expand the clinical spectrum of odontochondroplasia (ODCD) and demonstrate the existence of common variantsadmin2022-10-03T09:58:18+02:00

X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience

X-linked hypophosphatemia and burosumab: Practical clinical points from the French [...]

X-linked hypophosphatemia and burosumab: Practical clinical points from the French experienceadmin2022-10-03T09:58:06+02:00

Defining a growing and maturing skeleton and its relevance in diseases that affect skeletal growth, such as X-linked hypophosphataemia (XLH)

Defining a growing and maturing skeleton and its relevance in [...]

Defining a growing and maturing skeleton and its relevance in diseases that affect skeletal growth, such as X-linked hypophosphataemia (XLH)admin2022-10-03T09:57:53+02:00

Oral health-related quality of life in X-linked hypophosphatemia and osteogenesis imperfecta

Oral health-related quality of life in X-linked hypophosphatemia and osteogenesis [...]

Oral health-related quality of life in X-linked hypophosphatemia and osteogenesis imperfectaadmin2022-10-03T09:57:38+02:00

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial [...]

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemiaadmin2022-10-03T09:57:26+02:00

About admin